Freya Pharma Solutions, a Netherlands-based late clinical stage company, announced on Wednesday that it has named Christa van Kan, MSc as its new director Clinical Operations, effective March 2023.
In this new role van Kan will be responsible for driving the confirmatory clinical development investigating Lybrido, an 'on demand' therapy for the treatment of premenopausal women suffering from Female Sexual Interest/Arousal Disorder (FSIAD).
van Kan has over 25 years of clinical operations and trial management experience. She has served as interim director Clinical Operations at Healx. She co-founded and held the position of director Clinical Operations of PSR Group.
van Kan has an MSc degree in Biomedical Sciences from the State University Leiden in The Netherlands.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer